Dr. Carl R. Thornfeldt is the CEO and Founder of Episciences, Inc. He is a practicing dermatologist with over 30 years of skin research experience and 22 U.S. patents granted. Dr. Thornfeldt has published over 40 scientific articles, including chapters in nine textbooks focused on cosmeceuticals, drug delivery, natural products and dermatology treatments. He has also spent twenty-five years focusing on researching abnormalities of the skin barrier, cutaneous inflammation, drug delivery, herbs and disease therapies.

“I know there are many compelling theories about skin. Through years of research and treating my patients, I found a new way to make a profound effect on aging and skin health in my patients. As a physician, I knew my peers would want evidence and in my practice, so I have spent a lifetime on proving the safety and efficacy of our product. I believe that Epionce helps me be a better doctor.”

Dr. Thornfeldt received his M.D. from the Oregon Health Sciences University. Soon after, he spent three years in family practice for the U.S. Navy, and completed his dermatology residency at University Hospital, San Diego, California. While running his private practice and conducting research, Dr. Thornfeldt has co-founded and held the position of CEO at several privately and publicly held companies. Several of his therapeutic technologies are currently on the market through major pharmaceutical companies.

Dr. Thornfeldt presents at international, national and regional scientific meetings including the Chinese Academy of Dermatology, the American Academy of Dermatology, THE Aesthetic Show, the American Society for Laser Medicine and Surgery, the National Society of Cosmetic Physicians, the American Society of Dermatologic Surgery and the Facial Aesthetics Conference and Expo in London. In 2010 his first full-length textbook – “The New Ideal in Skin Health” – was released.

In 2003 and 2005, Dr. Thornfeldt was selected as one of the top 50 doctors in the U.S. by The Sinatra Health Report. He was the only dermatologist on the list. In 2014, he was presented with the Innovators in Dermatology award at the Cosmetic Surgery Forum.

Want to stay in touch?

The FDA defines cosmetics as "articles…applied to the human body...for cleansing, beautifying, promoting attractiveness, or altering the appearance" The majority of Epionce® products described on this website are intended to meet this definition. These Epionce® products and their associated statements have not been approved or evaluated by the FDA and are not intended to be drug products that diagnose, treat, cure, or prevent any disease or condition.

Epionce Active Shield Lotion SPF 30+ and Ultra Shield Lotion SPF 50 are considered over-the-counter drug products. They are formulated and marketed pursuant to the FDA’s governing regulations set forth at 21 C.F.R. Part 352.